According to Neil Gleghorn, CEO of UK-headquartered artwork management specialist Kallik, the full impact of imminent Classification, Labelling And Printing (CLP) changes have yet to be fully grasped by the packing industry. So beware!

While the packaging sector is no stranger to a fast-changing business environment, it is nevertheless about to face a storm of compliance change for which it has to be ready.

CLP, the key upcoming Classification, Labelling and Packaging European Union regulation, is the heavy weather in question. The problem is that even for organisations confident they are fully abreast of its intricacies or even fully engaged in implementing them, customers on the front line of CLP preparations are reporting that there are unforeseen CLP challenges that may well trip you up.

To read the full article, please visit the Packaging Europe website: http://www.packagingeurope.com/Packaging-Europe-News/61304/What-You-Dont-Know-Yet-About-CLP.html

 

 

By Neil Gleghorn, Co-Founder and CEO, Kallik

Are you having an ‘Upgrade Upset’ at the moment?

What’s one of those?

Well, it’s simple: most software product companies work like this when they start off; write some code for customer X. And when we win customer Y, as they don’t have quite the same requirements in terms of functionality as customer X, we’ll add some more code in for them.

And so the codebase grows as the customer roster does. Oh, hello customer P and Q: sure we can help you – let’s just bend the code a bit and fiddle with that bit and bespoke this element to make it work in your environment!

That approach works fine until you become a victim of your own success. That’s to say, you need to release an upgrade version of the system. That’s the whole system of course – the bit that includes not just the first bits, but what you wrote for X and Y and P and Q and everyone else along the way.

Out comes the upgrade.

And down go at least some customers – let’s call them C and D – whose needs were covered well enough before, but all the changes have stopped that…

And in more cases than you’d like to think, the revised code now also doesn’t work so well for customer P!

Welcome to the nightmare that too much commercial software often strays into – aka the Upgrade Upsets.

Consistent and configurable

The problem of upgrades that generate issues for customers is one that is particularly acute in the pharmaceutical industry.

I talk to a lot of customers in that sector that won’t upgrade a core package as they (and, let’s be honest, the vendor) don’t have enough visibility into the ramifications of changes.

By trying to please and win new customers, the developers have taken too much of a gamble on the original core functionality being sound and dependable. Often, it isn’t, and often after a surprisingly short time in the market.

We never wanted our customers to face this situation at Kallik. Nor did we, as developers, want the hassle of trying to work out why poor customer L or N was experiencing all those bugs with the latest release.

So we made a fundamental design decision at the start of Kallik: we’d only ever have one codebase.

We wanted a single codebase that all customers’ solutions would be built from and which could be configured to provide each individual customer’s needs, so we’d never have to worry about modifications that wouldn’t suit everyone.

It meant that it took us longer to create and more to fund.

But it was worth it – as our customers never have the Upgrade Upset.

But how, I hear you ask, can the same codebase help different customers with different needs?

In the first place, we built a huge amount of functionality into the core Kallik AMS (Artwork Management Solution) to ensure customers wouldn’t have too little to choose from.

But more importantly, we gave customers the ability to configure at will.

That means you can change and adapt the system – fine-tuning it to your specific needs on an ‘as-necessary’ basis.

And as a result, our pharma customers can move to any new version we release as they want – because they know the improvements we’ve taken pains to include won’t de-rail them, but only ever help them.

 

 

By Neil Gleghorn, Founder and CEO of Kallik

Here’s what many of our customers think they need to do:

Have one sophisticated marketing artwork process – covering all their customer needs; and then have another one for the factory – where the focus is just on production labelling.

Here’s the problem: this is a completely artificial distinction. It’s also one that really doesn’t help you.

Here’s a real life example of why that’s so. A customer who used to generate and approve artwork which was then sent to the factory for printing and labelling the products … only for the factory then to rebuild all the artworks in their labelling system. Which not surprisingly not only meant all sorts of problems re-entering data, copying by hand, but also real costly problems with labelling errors.

For a set of historical reasons, we’ve ended up with two needlessly different approaches to artwork.

We have at the factory labelling end a series of systems in place that crank out thousands of labels and a different process elsewhere.

This is an illogical division. They are two ends of the same process!

I think this has arisen in the first place from some feeling that you didn’t need to do the ‘pretty’ stuff at the coal face and that the artwork needed to be kept separate.

But when you think about it, it doesn’t matter if it’s a flyer, a leaflet, a carton print or specific product labelling: it’s all customer communication, it’s all content that you need to get looking good, right and be easily maintained.

Kallik, of course, is all about managing content. We encourage you to start thinking in terms of managing your artwork and labelling content as one coherent whole, not as distinct, disconnected documents.

However, there’s just no need to think about it in these terms. What I am saying, based on my experience of seeing this process managed so ‘disconnectedly’, is that your factory labelling does not need to be managed any differently to any other artwork – and it would make your business a lot simpler if it was folded into the same unified process you employ at head office.

Artificial barrier

The good news is that we have the technology in the main Kallik AMS (Artwork Management Solution) to let you stop setting up this artificial barrier – and instead, work with one set of designs and information across your business.

Unless you like using the artworks that you spent all that money and time crafting as some sort of ‘design guide’ – rather than using the actual art for the items you want out of the door and on the way to the customer as soon as possible!

We’ll be talking about this more in our Kallik Webinar at 2pm (BST) on 20th August – ‘Taking a Holistic Approach To Factory Labelling and Artwork Management’ . Find out more and register here if you’re interested: https://www.kallik.com/webinars/

HS061214_SM_2562Kallik’s co-founder and CEO Neil Gleghorn has just been recognised as one of the 100 most influential people in the UK’s pharmaceutical sector. Neil shares his reactions to this peer award – as well as his reflections on the changes he’s seen in the market over the 20-plus years Kallik’s been selling to customers

It’s not often that one of your most important markets turns round and says, ‘Well done.’ Getting on to the PharmaVOICE 100 list is thus quite a landmark.

I have to say, great as it is to have my name on this, this isn’t really about me as an individual. It may sound a bit ‘Oscar Speech’ – but this really is all about the work of everyone here at Kallik, from the most junior team member all the way up to the board, our partners and everyone who’s been part of the journey.

Most important of all, is of course our customers. It’s been all about them. More specifically, it’s been about a dialogue with them that often has lasted years based on our ability to look at their organisations as a whole to suggest where the gaps are and where they could look to prise out efficiencies.

You have to understand the reality of the sector to see what we mean here. For the regulatory team, the marketing team, the R&D team in those organisations – they don’t always see the full picture, the wider organisational flow, that a third party like a Kallik can. What we have been doing – is to suggest ways to link together better and save time and money.

That aspect – better ways to save, and more ways to increase profitability – has been getting more and more of a focus for the sector too. No pharma leader wants to see any time wasted in terms of the lifetime of their company’s products. These guys can’t afford to waste any of that precious time, given the increasingly competitive nature of their globalised market space.

 

 

 

Labelling content & Artwork management leader Kallik’s founder and CEO Neil Gleghorn has been selected as one of the 100 most influential people in the pharmaceutical sector worldwide –

Tamworth, UK August 4, 2014 –Labelling Content & Artwork Management leader Kallik is delighted to announcethat its founder and CEO Neil Gleghorn has just been recognised as one of the 100 most influential people on the global pharmaceutical stage.

The honour is confirmed by Neil being named to the landmark PharmaVOICE 100 List published by the sector’s leading independent editorial publication, PharmaVOICE.

Established nine years ago, The PharmaVOICE 100 is an annual list of individuals determined by their peers as having made the most consistent, outstanding contribution to the life sciences industry, an industry whose UK representatives generate over £50bn in sales every year according to government statistics.

According to the publishers, winners of PharmaVOICE 100 places illustrate what it means to think bigger, do more, and lead with passion and integrity, with all nominations decided by members of the sector.

“I am extremely honoured to receive this industry recognition,” said Neil.

“It is one of the most important peer awards in the pharmaceutical industry, and is testament to the work of everyone here at Kallik – not just me, but everyone from the most junior team member all the way up to the board, our partners and everyone who’s been part of the journey – and most important of all, our customers.”

A long-lasting dialogue

Neil’s extensive knowledge and understanding of the pharma industry’s specific challenges was key to his winning a PharmaVOICE 100 place. That is a knowledge base that he has used to develop forward-thinking solutions that help achieve efficiency and compliance as well as form the basis for on-going dialogues with customers about the long-term challenges they face. “What a third party like a Kallik can do is see the gaps that siloed teams in procurement, regulatory or marketing in a pharmaceutical company just can’t,” he said. “We use that perspective to develop the kind of systems that the pharmaceutical companies of today are increasingly recognising as vital in maximising their opportunity in the market.”

About Kallik

Kallik is a global provider of software solutions that simplify complex artwork management, generation and approval challenges for regulated industries. Its systems help such organisations to reduce the risk of product recall, guarantee product and brand consistency, mitigate risk and reduce costs.

Based on technologies using a structured data-centric approach, Kallik’s solutions leverage and repurpose content to automatically generate artwork.  This enables businesses to remove duplication, track content and rapidly change messaging to respond to new market and regulatory challenges. Formed in 2001, Kallik’s founders and senior management team have a rich heritage in the packaging and labelling industry. The flagship AMS360™ Automated Artwork Management solution was devised based on this insider knowledge of the sector and today underpins the businesses of companies including Sealed Air, Estee Lauder, Coloplast, Integra, Mary Kay and Unilever.

More at www.kallik.com or follow us on Twitter @KallikAMS

About PharmaVOICE PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE, with the largest distribution in its market sector, is delivered to more than 34,000 BPA-qualified subscribers, which include executives from pharmaceutical manufacturing, biotechnology, drug discovery, research & development, contract research, drug delivery, and device/diagnostic companies. The publication also targets decision makers at healthcare advertising, marketing, medical education, public relations, information technology, contract sales, traditional and nontraditional media, and other service support companies and organizations. The publication also reaches more than 100,000 users with its digital edition, which contains original exclusive bonus content. PharmaVOICE’s unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics.

More at www.pharmavoice.com